nanotech-investing Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
nanotech-investing Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
nanotech-investing Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
nanotech-investing Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
nanotech-investing Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
nanotech-investing Silo Pharma Acquires ResearchCoin Crypto Tokens in Support of Decentralized Science
nanotech-investing Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
nanotech-investing Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
nanotech-investing Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
nanotech-investing Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
nanotech-investing Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
nanotech-investing Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
nanotech-investing Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
nanotech-investing Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
nanotech-investing Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505 Pathway
